Abrocitinib and Ticagrelor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 10, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ticagrelor
Abrocitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Ticagrelor (Brilinta) is a blood thinner that keeps your platelets from clumping, so you bruise and bleed more easily. Abrocitinib (Cibinqo), a medicine for eczema, can also affect your platelets. When you take both, those effects add up and your risk of bleeding goes higher.
Because of this, the makers of abrocitinib say it should not be combined with ticagrelor during the first 3 months of abrocitinib treatment. This is based on caution rather than lots of real-world reports, but it is taken seriously. Please don't stop either drug on your own. Talk with your pharmacist or doctor so they can pick the safest plan for you.
Effect: Additive impairment of hemostasis, increasing bleeding risk. Both agents affect platelet function (ticagrelor via reversible P2Y12 inhibition; abrocitinib via JAK1-mediated effects, including thrombocytopenia risk).
- Direction: Additive PD interaction, increased bleeding potential.
- Severity: Contraindicated per abrocitinib labeling with antiplatelet agents (except low-dose aspirin, 81 mg/day or less) during the first 3 months of therapy.
- Onset: Unspecified.
- Evidence: Theoretical.
- Management: Avoid concurrent use during the initial 3-month period. If antiplatelet therapy is essential, coordinate with the prescriber regarding regimen choice and monitor for bleeding.
What happens
Increased risk of bleeding
Interaction Deep Dive
Giving abrocitinib together with antiplatelet drugs is contraindicated during the initial 3 months of therapy, with the exception of low-dose aspirin (81 mg per day or less), because of a heightened bleeding risk1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
What your care team may do:
- Avoid using ticagrelor together with abrocitinib during the first 3 months of abrocitinib treatment, since this combination is labeled as contraindicated.
- Consider whether a different plan is appropriate (for example, low-dose aspirin at 81 mg daily or less may be allowed where an antiplatelet is needed).
- Watch you more closely for signs of bleeding if therapy overlaps.
What you should do: Keep taking both exactly as prescribed for now, and do not stop either one on your own. Tell your pharmacist or prescriber that you take both so they can tailor the safest plan. Report unusual bruising, nosebleeds, blood in urine or stool, or bleeding that won't stop.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abrocitinib and Ticagrelor together?
Ticagrelor and abrocitinib both raise bleeding risk, and this combination is contraindicated during the first 3 months of abrocitinib. Do not stop either drug yourself; contact your prescriber or pharmacist to arrange a safer plan. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abrocitinib and Ticagrelor interaction?
It is rated contraindicated. These should generally not be used together.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abrocitinib and Ticagrelor interaction managed?
What your care team may do: Avoid using ticagrelor together with abrocitinib during the first 3 months of abrocitinib treatment, since this combination is labeled as contraindicated. Consider whether a different plan is appropriate (for example, low-dose aspirin at 81 mg daily or less may be allowed where an antiplatelet is needed). Watch you more closely for signs of bleeding if therapy overlaps.… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abrocitinib or Ticagrelor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: CIBINQO(TM) oral tablets, abrocitinib oral tablets. Pfizer Labs (per FDA), New York, NY, 2022. DailyMed
Keep reading about Ticagrelor
Keep reading about Abrocitinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist